sorafenib + temsirolimus

Sorafenib + temsirolimus is an investigational combination therapy consisting of two small molecule drugs with distinct but potentially complementary mechanisms of action. Sorafenib is a multikinase inhibitor that targets Raf kinases, vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor-beta (PDGFR-β), thereby inhibiting tumor cell proliferation and angiogenesis. Temsirolimus is an allosteric inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), a key regulator of cell growth and metabolism. The rationale for combining these agents lies in their ability to simultaneously inhibit tumor proliferation pathways and angiogenesis, as well as to overcome resistance mechanisms associated with single-agent targeted therapies. This combination has been studied in phase I/II clinical trials for various advanced solid tumors including glioblastoma multiforme, hepatocellular carcinoma (HCC), and radioactive iodine-refractory thyroid cancer[1][2][3]. While the combination demonstrated acceptable safety at reduced doses compared to monotherapy regimens, efficacy endpoints such as progression-free survival were not met in several studies.

Brand names

Nexavar

Other names

none